Umavida Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 17-11-2024
- Paid Up Capital ₹ 0.10 M
as on 17-11-2024
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 40.00 Cr
as on 17-11-2024
- Revenue 126456.74%
(FY 2023)
- Profit 8252.96%
(FY 2023)
- Net Worth 19396.67%
(FY 2023)
- Total Assets 4.61%
(FY 2023)
About Umavida Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹40.00 Cr.
Varun Patel, Jagdishbhai Desai, Vipul Chaudhari, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24299GJ2019PTC107172
- Company No.
107172
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Mar 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Mahesana, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Umavida Pharma?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Varun Patel  | Director | 20-Mar-2019 | Current |
| Jagdishbhai Desai | Director | 20-Mar-2019 | Current |
| Vipul Chaudhari | Director | 20-Mar-2019 | Current |
| Bindiya Gohel | Director | 03-Aug-2022 | Current |
| Fenil Shah | Director | 20-Mar-2019 | Current |
| Shil Shah | Director | 20-Mar-2019 | Current |
Financial Performance of Umavida Pharma.
Umavida Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 126456.74% increase. The company also saw a substantial improvement in profitability, with a 8252.96% increase in profit. The company's net worth Soared by an impressive increase of 19396.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Umavida Pharma?
In 2023, Umavida Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Avensis Pharmaceuticals Private LimitedActive 10 years 9 months
Jagdishbhai Desai is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 17 Feb 2022 | ₹20.00 Cr | Open |
Hdfc Bank Limited Creation Date: 04 Feb 2022 | ₹20.00 Cr | Open |
How Many Employees Work at Umavida Pharma?
Umavida Pharma has a workforce of 70 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Umavida Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Umavida Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
